The investigators will track 250 multiple myeloma patients across Canada over time, using new lab tests to evaluate their blood and bone marrow, as they receive standard of care treatment. The main hypothesis is that these tests will allow clinicians to better diagnose and manage multiple myeloma, improving patients' quality of life overall.
Eligibility
Sex
ALL
Min age
19 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria:
* Ability to give informed consent
* Diagnosed with active multiple myeloma
* Consented to participation in Myeloma Canada Research Network (MCRN) database project
* Previously untreated and eligible for autologous stem-cell transplantation (ASCT)
Exclusion Criteria:
* Ineligible for ASCT
* Does not consent to participate in MCRN database project
Primary outcome measure(s)
Sensitivity of Minimal Residual Disease (MRD) Assays — 100 days post-treatment Comparison of the sensitivity of two leading-edge MRD assays - (1) multiparameter flow cytometry (MFC), and (2) immunoglobulin gene sequencing (IgS) - in patients who meet the conventional definition of complete remission post-treatment.
Sensitivity of Minimal Residual Disease (MRD) Assays — 12 months post-maintenance therapy Comparison of the sensitivity of two leading-edge MRD assays - (1) multiparameter flow cytometry (MFC), and (2) immunoglobulin gene sequencing (IgS) - in patients who meet the conventional definition of complete remission post-treatment.
Trial sites (9)
Facility
City
Region
Status
Tom Baker Cancer Centre
Calgary
Alberta
Cross Cancer Institute
Edmonton
Alberta
Vancouver General Hospital
Vancouver
British Columbia
CancerCare Manitoba
Winnipeg
Manitoba
Saint John Regional Hospital (Horizon Health Network)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.